TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34120363

Group type: EXPERIMENTAL
Intervention: Protease supplementation at 500 g/ton in low protein diet (29% CP)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Protease supplementation at 250 g/ton in normal protein diet (30% CP)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control -ve (low protein diet, 29% CP without protease)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control +ve (normal protein diet, 30% CP without protease)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Protease supplementation
Number of subjects: 360
Study: 34301320

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (W-3 FAs)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: combined omega-3 and nanocurcumin
Number of subjects: 80

Group type: COMPARATOR
Intervention: nanocurcumin
Number of subjects: 80

Group type: COMPARATOR
Intervention: control group
Number of subjects: 80
Study: 35642288

Group type: EXPERIMENTAL
Intervention: 24-week basketball training programme (3 times per week, 60 min per session)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (maintained daily activities without special physical training)
Number of subjects: 22
Study: 34103345

Group type: EXPERIMENTAL
Intervention: Restarting antiplatelet therapy
Number of subjects: 537

Group type: COMPARATOR
Intervention: Avoiding antiplatelet therapy
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: DWI+ lesion presence
Number of subjects: 537
Study: 33139664

Group type: EXPERIMENTAL
Intervention: Health Arcade prototype multidomain intervention based on physical and cognitive training using gamification technologies
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Health Arcade prototype multidomain intervention
Number of subjects: 40
Study: 36030965

Group type: EXPERIMENTAL
Intervention: PVI + atrial LVA ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 0
Study: 32769519

Group type: EXPERIMENTAL
Intervention: 30 units of abobotulinumtoxinA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 45 units of abobotulinumtoxinA
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0 units of abobotulinumtoxinA (placebo)
Number of subjects: 50
Study: 34039013

Group type: EXPERIMENTAL
Intervention: Apalutamide (240 mg/day) plus continuous androgen deprivation therapy (ADT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus continuous androgen deprivation therapy (ADT)
Number of subjects: 0
Study: 35417910

Group type: EXPERIMENTAL
Intervention: SWiM‐C
Number of subjects: 388

Group type: COMPARATOR
Intervention: Standard advice
Number of subjects: 388
Study: 34620907

Group type: EXPERIMENTAL
Intervention: Anti-adhesion agent Collabarrier
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (no anti-adhesion agent)
Number of subjects: 100
Study: 32053937

Group type: EXPERIMENTAL
Intervention: Exergaming group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Conventional physical training group
Number of subjects: 15

Group type: COMPARATOR
Intervention: No training group (control)
Number of subjects: 15
Study: 35216853

Group type: EXPERIMENTAL
Intervention: Intervention message targeting the fundamental motive of kin care
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Intervention message targeting the fundamental motive of disease avoidance
Number of subjects: 969

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 969
Study: 34887317

Group type: EXPERIMENTAL
Intervention: Albuterol/budesonide (180/160 µg or 180/80 µg, two actuations of 90/80 µg or 90/40 µg)
Number of subjects: 3100

Group type: COMPARATOR
Intervention: Albuterol (180 µg, two actuations of 90 µg)
Number of subjects: 3100
Study: 35191512

Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 4464

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 4464

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 4464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4464
Study: 33158230

Group type: EXPERIMENTAL
Intervention: SBIRT
Number of subjects: 750

Group type: COMPARATOR
Intervention: HHC
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: SBIRT with NRT
Number of subjects: 750
Study: 33205741

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (radiation-attenuated, 2.7 × 10^6 PfSPZ, three doses at 8-week intervals)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PfSPZ-CVac (infectious, 1.0 × 10^5 PfSPZ, three doses at 4-week intervals)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PfSPZ-CVac
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Number of subjects: 28
Study: 33222559

Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baricitinib 2-mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baricitinib 1-mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33587407

Group type: EXPERIMENTAL
Intervention: 6 weeks Exclusive Enteral Nutrition (EEN) followed by 6 weeks 25% Partial Enteral Nutrition (PEN)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 6 weeks 50% PEN with CD exclusion diet followed by 6 weeks 25% PEN with exclusion diet
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: DXA scans performed at diagnosis
Number of subjects: 29
Study: 32341595

Group type: EXPERIMENTAL
Intervention: Rapid glucocorticoid tapering
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional glucocorticoid tapering
Number of subjects: 0
Study: 34266323

Group type: EXPERIMENTAL
Intervention: Comprehensive, domiciliary, mobile application-guided and tele-monitored cardiac rehabilitation program (n=49)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard rehabilitation treatment (control group) (n=48)
Number of subjects: 100
Study: 34263971

Group type: EXPERIMENTAL
Intervention: Licogliflozin 50 mg TID
Number of subjects: 0
Study: 33136923

Group type: EXPERIMENTAL
Intervention: Brexpiprazole (1, 2, or 3 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brexpiprazole (OLE, flexible-dose 0.5-3 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Number of subjects: 0
Study: 35844045

Group type: EXPERIMENTAL
Intervention: Wide-pulse NMES (WP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Narrow-pulse NMES (NP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Wide-pulse NMES with tendon vibration (WP+VIB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: All NMES conditions
Number of subjects: 16
Study: 35496721

Group type: EXPERIMENTAL
Intervention: Stabilization exercises (SEs) combined with pelvic floor muscle (PFM) exercises
Number of subjects: 48

Group type: COMPARATOR
Intervention: Stabilization exercises (SEs) alone
Number of subjects: 48
Study: 35776517

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact on caregivers
Number of subjects: 17
Study: 32233639

Group type: EXPERIMENTAL
Intervention: Stereotactic soft channel puncture and drainage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine treatment with small bone window hematoma removal
Number of subjects: 60
Study: 35815055

Group type: EXPERIMENTAL
Intervention: Composite skin graft
Number of subjects: 78

Group type: COMPARATOR
Intervention: Autologous skin graft
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: MRI imaging
Number of subjects: 78
Study: 33357499

Group type: EXPERIMENTAL
Intervention: Benralizumab (30 mg every 8 weeks, first three doses given 4 weeks apart)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 656

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656
Study: 35294812

Group type: EXPERIMENTAL
Intervention: donidalorsen (80 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 33794517

Group type: EXPERIMENTAL
Intervention: AI model using modified Mask R-CNN algorithm
Number of subjects: 13228

Group type: COMPARATOR
Intervention: Three attending orthopedic doctors
Number of subjects: 13228

Group type: EXPERIMENTAL
Intervention: AI model
Number of subjects: 13228
Study: 33129289

Group type: EXPERIMENTAL
Intervention: Nano-Curcumin 80 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prednisolone 10 mg
Number of subjects: 60
Study: 33766186

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 120
Study: 33568279

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid administration at induction for hemiarthroplasty
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid administration at induction for intramedullary nail fixation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group for hemiarthroplasty (no TXA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group for intramedullary nail fixation (no TXA)
Number of subjects: 51
Study: 36356829

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Standard-dose nVNS
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High-dose nVNS
Number of subjects: 69
Study: 33894738

Group type: EXPERIMENTAL
Intervention: Manipulation under anaesthesia (MUA)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Lysis of adhesions (LOA)
Number of subjects: 360
Study: 32276257

Group type: EXPERIMENTAL
Intervention: Occipital anchors
Number of subjects: 14

Group type: COMPARATOR
Intervention: Occipital plate and screws
Number of subjects: 14
Study: 36252858

Group type: EXPERIMENTAL
Intervention: Centralized digital workflow (c‐DW)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Laboratory digital workflow (l‐DW)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both workflows
Number of subjects: 59
Study: 32778471

Group type: EXPERIMENTAL
Intervention: High Phosphatemic Index (PI) test meals
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low Phosphatemic Index (PI) test meals
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control meals
Number of subjects: 30
Study: 35103074

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC)
Number of subjects: 280
Study: 33306558

Group type: EXPERIMENTAL
Intervention: Preoperative video-based opioid education
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard of care for pain management education (Control)
Number of subjects: 130
Study: 32282525

Group type: EXPERIMENTAL
Intervention: Postpartum pelvic floor physical therapy (PFPT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study: 35983532

Group type: EXPERIMENTAL
Intervention: CPL NPWTi
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline NPWTi
Number of subjects: 60
Study: 34698464

Group type: EXPERIMENTAL
Intervention: Auriculotherapy with miniature bian needle
Number of subjects: 74

Group type: COMPARATOR
Intervention: Proper physical exercise
Number of subjects: 74
Study: 33380704

Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (traditional therapy + placebo)
Number of subjects: 45
Study: 35771353

Group type: EXPERIMENTAL
Intervention: BNT162b1 mRNA vaccine (10 µg dose)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: BNT162b1 mRNA vaccine (30 µg dose)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: BNT162b1 mRNA vaccine (in older participants)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: BNT162b1 mRNA vaccine
Number of subjects: 141
Study: 34065775

Group type: EXPERIMENTAL
Intervention: Mobile diabetes management
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Mobile diabetes management with HCP feedback
Number of subjects: 181

Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 181
Study: 32821494

Group type: EXPERIMENTAL
Intervention: Continuous Wave Transscleral Cyclophotocoagulation (CW‐TCP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Micropulse Transscleral Cyclophotocoagulation (MP‐TCP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nontreated control
Number of subjects: 12
Study: 35552938

Group type: EXPERIMENTAL
Intervention: Surgery with neutral argon plasma (PlasmaJet)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Without PlasmaJet (control group)
Number of subjects: 327
Study: 34335853

Group type: EXPERIMENTAL
Intervention: Warm water and ginger (GI)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Warm water and mustard (MU)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Warm water only (WA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: All three conditions (GI, MU, WA)
Number of subjects: 17
Study: 35234732

Group type: EXPERIMENTAL
Intervention: Sugar-tong splint
Number of subjects: 89

Group type: COMPARATOR
Intervention: Clamshell splint
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both splint types
Number of subjects: 89
Study: 32926823

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35314431

Group type: EXPERIMENTAL
Intervention: Non-antibiotic treatment options
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Postponing antibiotic treatment by up to 3 days
Number of subjects: 26
Study: 34597318

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Soft occlusive splint therapy (OST)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (waitlist group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 112
Study: 32390725

Group type: EXPERIMENTAL
Intervention: 2/0/X tempo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 4/0/X tempo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 6/0/X tempo
Number of subjects: 21
Study: 33128187

Group type: EXPERIMENTAL
Intervention: LA strain (LAS) and strain rate (LASR) assessment using Feature Tracking software (QStrain v2.0)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LA volumes (LAV) and emptying fraction (LAEF) calculated using the biplane area length method (QMass v8.1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intra- and inter-observer variability assessment
Number of subjects: 60
Study: 32649365

Group type: EXPERIMENTAL
Intervention: Ala-Gln at 12g/day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ala-Gln at 3g/day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ala-Gln at 6g/day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ala-Gln at 3g/day, 6g/day, and 12g/day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ala-Gln
Number of subjects: 140

Group type: COMPARATOR
Intervention: Gly placebo at 12.5g/day
Number of subjects: 140
Study: 33303191

Group type: EXPERIMENTAL
Intervention: Pressed lithium disilicate (LD) crowns
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Translucent zirconia (TZ) crowns
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comparison of LD and TZ crowns
Number of subjects: 62

Group type: COMPARATOR
Intervention: Assessment of color match
Number of subjects: 62
Study: 32916021

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic prostatectomy (RALP)
Number of subjects: 4003

Group type: COMPARATOR
Intervention: Retropubic radical prostatectomy (RRP)
Number of subjects: 4003

Group type: EXPERIMENTAL
Intervention: Surgeon volume
Number of subjects: 4003
Study: 36221988

Group type: EXPERIMENTAL
Intervention: Increased fluid consumption (≥2.2 L total beverage intake, with 1.9 L being water)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Maintaining habitual fluid intake (control)
Number of subjects: 13
Study: 34073918

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT‐A) injection
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: BoNT‐A injection (time between stroke onset and injection ≤90 days)
Number of subjects: 83
Study: 34933568

Group type: EXPERIMENTAL
Intervention: REL-1017 25 mg/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: REL-1017 50 mg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 32567443

Group type: EXPERIMENTAL
Intervention: Intraoperative monitoring of somatosensory evoked potentials (SEPs) and motor evoked potentials (MEPs)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No intraoperative monitoring (Control group)
Number of subjects: 48
Study: 34146844

Group type: EXPERIMENTAL
Intervention: Family-centered care intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 152
Study: 35381904

Group type: COMPARATOR
Intervention: PEEP 0 cmH2O
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PEEP 5 cmH2O
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PEEP 10 cmH2O
Number of subjects: 25
Study: 34278803

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg once daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 33714847

Group type: EXPERIMENTAL
Intervention: Nelotanserin 80 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 36115142

Group type: EXPERIMENTAL
Intervention: Telemedicine assessment
Number of subjects: 58

Group type: COMPARATOR
Intervention: In-person assessment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Comparison of telemedicine and in-person assessments
Number of subjects: 58
Study: 33278897

Group type: EXPERIMENTAL
Intervention: Thermal therapy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Thermal therapy + exercises
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control
Number of subjects: 69
Study: 35753828

Group type: EXPERIMENTAL
Intervention: Arthroscopic Wafer Procedure (AWP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ulnar Shortening Osteotomy (USO)
Number of subjects: 60
Study: 33482631

Group type: EXPERIMENTAL
Intervention: Taking ≥8 medications
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications (PIMs)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Cutoff of 5 medications
Number of subjects: 439
Study: 33204249

Group type: EXPERIMENTAL
Intervention: Dance Intervention (DI)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (life as usual)
Number of subjects: 76
Study: 35762448

Group type: EXPERIMENTAL
Intervention: Cloti‐Xa™ (40 mg/0.4 ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cloti‐Xa™ and Clexane®
Number of subjects: 24
Study: 34728527

Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy
Number of subjects: 760

Group type: COMPARATOR
Intervention: No retroperitoneal node dissection
Number of subjects: 760
Study: 32003647

Group type: EXPERIMENTAL
Intervention: Eccentric Exercises (EE)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Eccentric + Isometric Exercises (EE + ISO)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Symptomatic Insertion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Symptomatic Midportion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Midportion vs Insertion
Number of subjects: 42
Study: 33564120

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) combined with standard chemotherapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard chemotherapy alone (control)
Number of subjects: 85
Study: 34762724

Group type: EXPERIMENTAL
Intervention: US combined with limited radiography (UR group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiography only (RO group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50

Group type: COMPARATOR
Intervention: RO group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: UR group
Number of subjects: 50
Study: 33323287

Group type: EXPERIMENTAL
Intervention: Explicit strongly trainer‐guided debriefing
Number of subjects: 136

Group type: COMPARATOR
Intervention: Implicit and weakly guided debriefing
Number of subjects: 136
Study: 35183282

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychosocial counselling
Number of subjects: 0
Study: 33674679

Group type: EXPERIMENTAL
Intervention: 8 h-split (nocturnal sleep + 90-min afternoon nap)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 6.5 h-split (nocturnal sleep + 90-min afternoon nap)
Number of subjects: 112

Group type: COMPARATOR
Intervention: 8 h-continuous (no afternoon nap)
Number of subjects: 112

Group type: COMPARATOR
Intervention: 6.5 h-continuous (no afternoon nap)
Number of subjects: 112
Study: 33993715

Group type: EXPERIMENTAL
Intervention: eDASA+APP
Number of subjects: 77
Study: 35761030

Group type: EXPERIMENTAL
Intervention: Osc+ condition (heart rate variability biofeedback with slow paced breathing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Osc- condition (active control with little effect on heart rate oscillations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osc+ condition
Number of subjects: 0
Study: 33367742

Group type: EXPERIMENTAL
Intervention: 100 mg Clomiphene Citrate (CC) from Day 3 to 7 and 450 IU HMG
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 100 mg Clomiphene Citrate (CC) from Day 3 to 7 and 150 IU HMG
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo and 450 IU HMG
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo and 150 IU HMG
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 100 mg Clomiphene Citrate (CC) and 450 IU HMG
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 100 mg Clomiphene Citrate (CC) and 150 IU HMG
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 114
Study: 37745675

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (≤2 mg/kg daily) in SLS I
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Oral mycophenolate mofetil (1500 mg twice daily) in SLS II
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (≤2 mg/kg daily) in SLS II
Number of subjects: 300

Group type: COMPARATOR
Intervention: Active treatment groups pooled from SLS I and SLS II
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: SLS II
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: SLS I
Number of subjects: 300
Study: 34365645

Group type: EXPERIMENTAL
Intervention: Controlled regulation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Autonomous regulation
Number of subjects: 39
Study: 32966294

Group type: EXPERIMENTAL
Intervention: Guardix‐SG®
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (no Guardix‐SG®)
Number of subjects: 83